Congestive Heart Failure
Congestive heart failure (CHF) describes the condition of fluid build-up in the body as the heart inefficiently fills with or pumps out blood. CHF results from other conditions that weaken the heart muscle including coronary artery disease, myocardial infarction, cardiomyopathy, and hypertension, and is a major public health concern.
Interventions of interest: CardioMEMS™ HF System (St. Jude Medical) and sacubitril/valsartan (Entresto™, Novartis)
Date of review: September 2015
For questions or additional information, please contact firstname.lastname@example.org
The California Endowment, Oakland, CA
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting on Thursday, October 29, 2015 to discuss the comparative effectiveness and value of two interventions for patients with congestive heart failure (CHF) – the drug Entresto (a combination of valsartan and sacubitril, Novartis AG), and the CardioMEMS HF System (St. Jude Medical). The CardioMEMS HF System is a heart failure monitor manufactured by St. Jude Medical and approved by the FDA in May, 2014. Entresto is a drug for the treatment of heart failure with reduced ejection fraction and was approved by the FDA on July 7, 2015.
Public comments received on the Draft Evidence Report.
Research protocol posted to Open Science Framework: https://osf.io/7awvd/